



Boehringer  
Ingelheim

## TRIAL STATISTICAL ANALYSIS PLAN

<b>Document No.:</b>	<b>c43973288-01</b>
<b>BI Trial No.:</b>	<b>1305-0038</b>
<b>Title:</b>	Pharmacokinetics of R-BI 1015550 after single oral doses of BI 1015550 in Japanese healthy male subjects (open-label, non-randomised, and parallel group design) (Clinical Trial Protocol [c42256721-01])
<b>Investigational Product:</b>	BI 1015550
<b>Responsible trial statistician:</b>	[REDACTED]
	Phone: [REDACTED]
	Fax: [REDACTED]
<b>Date of statistical analysis plan:</b>	19 MAR 2024
<b>Version:</b>	1.0
<b>Page 1 of 25</b>	
<b>Proprietary confidential information</b>	
<b>© 2024 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.</b>	
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission.	

## 1. TABLE OF CONTENTS

<b>TITLE PAGE</b> .....	<b>1</b>
<b>1. TABLE OF CONTENTS</b> .....	<b>2</b>
<b>LIST OF TABLES</b> .....	<b>4</b>
<b>2. LIST OF ABBREVIATIONS</b> .....	<b>5</b>
<b>3. INTRODUCTION</b> .....	<b>6</b>
<b>4. CHANGES IN THE PLANNED ANALYSIS OF THE STUDY</b> .....	<b>7</b>
<b>5. ENDPOINTS</b> .....	<b>8</b>
<b>5.1 PRIMARY ENDPOINTS</b> .....	<b>8</b>
<b>5.2 SECONDARY ENDPOINTS</b> .....	<b>8</b>
<b>5.2.1 Key secondary endpoint</b> .....	<b>8</b>
<b>5.2.2 Secondary endpoints</b> .....	<b>8</b>
	
<b>6. GENERAL ANALYSIS DEFINITIONS</b> .....	<b>10</b>
<b>6.1 TREATMENTS</b> .....	<b>10</b>
<b>6.2 IMPORTANT PROTOCOL DEVIATIONS</b> .....	<b>11</b>
<b>6.3 INTERCURRENT EVENTS</b> .....	<b>11</b>
<b>6.4 SUBJECT SETS ANALYSED</b> .....	<b>12</b>
	
<b>6.6 HANDLING OF MISSING DATA AND OUTLIERS</b> .....	<b>13</b>
<b>6.7 BASELINE, TIME WINDOWS AND CALCULATED VISITS</b> .....	<b>13</b>
<b>7. PLANNED ANALYSIS</b> .....	<b>15</b>
<b>7.1 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS</b> .....	<b>16</b>
<b>7.2 CONCOMITANT DISEASES AND MEDICATION</b> .....	<b>17</b>
<b>7.3 TREATMENT COMPLIANCE</b> .....	<b>17</b>
<b>7.4 PRIMARY OBJECTIVE ANALYSIS</b> .....	<b>17</b>
<b>7.4.1 Main analysis</b> .....	<b>17</b>
	
<b>7.4.4 Supplementary analysis</b> .....	<b>18</b>
<b>7.5 SECONDARY OBJECTIVE ANALYSIS</b> .....	<b>18</b>
<b>7.5.1 Key secondary objective analysis</b> .....	<b>18</b>
<b>7.5.2 Secondary objective analysis</b> .....	<b>18</b>
<b>7.6 FURTHER OBJECTIVE ANALYSIS</b> .....	<b>18</b>
<b>7.7 EXTENT OF EXPOSURE</b> .....	<b>18</b>
<b>7.8 SAFETY ANALYSIS</b> .....	<b>18</b>
<b>7.8.1 Adverse Events</b> .....	<b>18</b>
<b>7.8.2 Laboratory data</b> .....	<b>20</b>
<b>7.8.3 Vital signs</b> .....	<b>21</b>
<b>7.8.4 ECG</b> .....	<b>21</b>
<b>7.9 OTHER ANALYSIS</b> .....	<b>21</b>

<b>8.</b>	<b>TIMEPOINT OF RELEASE OF TREATMENT INFORMATION .....</b>	<b>22</b>
<b>9.</b>	<b>REFERENCES .....</b>	<b>23</b>
<b>11.</b>	<b>HISTORY TABLE .....</b>	<b>25</b>

## **LIST OF TABLES**

Table 6.1: 1	Treatments and labels used in the analysis .....	10
Table 6.4: 1	Subject sets analysed .....	13
Table 11: 1	History table .....	25

## **2. LIST OF ABBREVIATIONS**

See Medicine Glossary:

<http://glossary>

Term	Definition / description
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
AUC <sub>0-∞</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
BMI	Body mass index
C <sub>max</sub>	Maximum measured concentration of the analyte in plasma
CTP	Clinical trial protocol
CTR	Clinical trial report
CV	Arithmetic Coefficient of Variation
DILI	Drug induced liver injury
gCV	Geometric Coefficient of Variation
gMean	Geometric Mean
Max	Maximum
Min	Minimum
N	Number non-missing observations
P10	10th percentile
P90	90th percentile
PKS	PK parameter analysis set
Q1	1st quartile
Q3	3rd quartile
R-BI 1015550	(active) R-enantiomer of BI 1015550
RPM	Report Planning Meeting
RAGe	Report Appendix Generator system
[REDACTED]	(inactive) S-enantiomer of BI 1015550
SD	Standard Deviation
TS	Treated Set
TSAP	Trial Statistical Analysis Plan
ULN	Upper Limit of Normal

### **3. INTRODUCTION**

As per ICH E9 (1), the purpose of this document is to provide a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and to include detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.

This trial statistical analysis plan (TSAP) assumes familiarity with the Clinical Trial Protocol (CTP), including Protocol Amendments. In particular, the TSAP is based on the planned analysis specification as written in CTP Section 7 “Statistical Methods and Determination of Sample Size”. Therefore, TSAP readers may consult the CTP for more background information on the study, e.g., on study objectives, study design and population, treatments, definition of measurements and variables, planning of sample size, randomization.

Study data (including data entered in the RAVE EDC system and external data provided by suppliers) will be stored in a Clinical Data Repository (CDR).

Pharmacokinetic (PK) parameters will be calculated using Phoenix WinNonlin™ software (version 8.1.1 or higher, [REDACTED]) or SAS Version 9.4 (or later version).

The statistical analyses will be performed within the validated working environment CARE, including SAS™ (current Version 9.4, by [REDACTED]), and a number of SAS™-based tools (e.g., macros for the analyses of AE data or laboratory data; Report Appendix Generator system (RAGe) for compilation/formatting of the CTR appendices).

#### **4. CHANGES IN THE PLANNED ANALYSIS OF THE STUDY**

All analyses as planned in the CTP will be performed and are described in more detail in this TSAP. No changes as compared to the planned analyses in the CTP will be done.

## **5. ENDPOINTS**

### **5.1 PRIMARY ENDPOINTS**

#### **Section 2.1.2 of the CTP:**

*The following pharmacokinetic parameters will be determined for R-BI 1015550:*

- *AUC<sub>0-∞</sub> (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)*
- *C<sub>max</sub> (maximum measured concentration of the analyte in plasma)*


### **5.2 SECONDARY ENDPOINTS**

#### **5.2.1 Key secondary endpoint**

This section is not applicable as no key secondary endpoints have been defined in the CTP.

#### **5.2.2 Secondary endpoints**

This section is not applicable as no secondary endpoints have been defined in the CTP.




**Boehringer Ingelheim**  
**TRIAL STATISTICAL ANALYSIS PLAN**  
**1305-0038**

**Page 9 of 25**

**c43973288-01**

Proprietary confidential information © 2024 Boehringer Ingelheim International GmbH or one or more of its affiliated companies.



## **6. GENERAL ANALYSIS DEFINITIONS**

### **6.1 TREATMENTS**

For basic study information on treatments to be administered, assignment of treatment groups, selection of doses, refer to CTP Sections 3 and 4.

This single dose trial is designed as open-label and non-randomised within parallel dose groups.

It is planned to include a total of 12 healthy male subjects in the trial (6 subjects in each dose group).

The trial drug will be administered as single oral dose. For details of dosage and formulation see Table 6.1:1 below.

Table 6.1: 1 Treatments and labels used in the analysis

<b>Treatment</b>	<b>Short label</b>
A BI 1015550 9 mg tablet, qd	BI 9mg
B BI 1015550 18 mg tablet, qd	BI 18mg

Based on this, the following study phases will be defined for the analysis of adverse events (AEs):

- **Screening**
  - Ranging from 0:00h on day of informed consent until time of first drug administration.
- **On treatment** (labelled with short label “BI 9mg”, “BI 18mg”)
  - Ranging from the time of trial drug administration until 7 days (168 h) thereafter OR until trial termination (0:00 h on the day after trial termination), whatever occurs first.
- **Follow-up** (labelled ‘F/U’)
  - Ranging from 7 days (168h) after trial drug administration until trial termination (0:00 h on the day after trial termination).

### **Section 7.2.5 of the CTP:**

*Note that AEs occurring after the last per protocol contact but entered before database lock will be reported to Pharmacovigilance only and will not be captured in the trial database.*

The following AE displays will be provided in the report:

- In Section 15.3 and Appendix 16.1.13.1.8 (for ClinicalTrials.gov only) of the CTR displays, the on treatment phase will be analysed (labelled with the short label of the study treatment). The screening and follow-up phases will not be included in this analysis.

The following totals will be provided in addition for Section 15.3:

- a total over all on treatment phases under BI treatment (“Total”)
- In Section 15.4 and Appendix 16.2 (Listings) of the CTR displays, the screening period, as well as the follow-up phases will additionally be included and no totals will be provided.

For detailed information on the handling of the treatments refer to Technical TSAP ADS (analysis data set) plan and Analysis Data Reviewers guide.

## **6.2 IMPORTANT PROTOCOL DEVIATIONS**

Data discrepancies and deviations from the CTP will be identified for all treated subjects. Consistency check listings (for identification of deviations of time windows) and a list of protocol deviations (e.g. deviations in drug administration, in blood sampling times, etc.) will be provided to be discussed at the Report Planning Meeting (RPM). At this meeting, all manual deviations identified at the sites by the CRAs and deviations too complex to program will be reviewed by the trial team to decide which are considered important. For definition of important protocol deviations (iPD), and for the process of identification of these, refer to the Boehringer Ingelheim (BI) SOP "Identify and Manage Important Protocol Deviations (iPD)" (2).

Important protocol deviation (iPD) categories are pre-specified in the iPD specification file (DV domain) (3). IPDs will be identified no later than in the Report Planning Meeting, and the iPD categories will be updated as needed.

If any iPDs are identified, they are to be summarised into categories and will be captured in the iPD specification file (DV domain) (3) and in the decision log (4). Both documents will be stored within the TMF in EDMS.

The iPDs will be summarized and listed in the CTR.

## **6.3 INTERCURRENT EVENTS**

This section is not applicable.

## **6.4 SUBJECT SETS ANALYSED**

### **Section 7.2.1.1 of the CTP:**

*Statistical analyses will be based on the following analysis sets:*

- *Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug. The treatment assignment will be determined based on the first treatment the subjects received. The treated set will be used for safety analyses.*
- *Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the treated set (TS) who provide at least one PK endpoint that was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability (as specified in CTP Section 7.2.1.2 'Pharmacokinetics'). Thus, a subject will be included in the PKS, even if he contributes only one PK parameter value for one period to the statistical assessment.*

*Descriptive (...) analyses of PK parameters will be based on the PKS.*

*The pharmacokinetic parameters listed in CTP Section 2.1 and 2.2.2 for R-BI 1015550, [REDACTED] will be calculated according to the relevant BI internal procedure.*

*Plasma concentration data and parameters of a subject will be included in the statistical pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the criteria specified below). Exclusion of a subject's data will be documented in the CTR.*

*Important protocol deviations may be*

- *Incorrect dose of trial medication taken*
- *Use of restricted medications*

*Plasma and urine concentrations and/or parameters of a subject will be considered as non-evaluable, if for example*


- *The subject experienced emesis that occurred at or before two times median t<sub>max</sub> of the respective treatment (Median t<sub>max</sub> is to be determined excluding the subjects experiencing emesis),*
- *Missing samples/concentration data at important phases of PK disposition curve.*

*Plasma concentration data and parameters of a subject which are flagged for exclusion will be reported with its individual values but will not be included in the statistical analyses.*

*Only concentration values within the validated concentration range and actual sampling times will be used for the calculation of pharmacokinetic parameters. Concentrations used in the pharmacokinetic calculations will be in the same format as in the bioanalytical report (that is to the same number of decimal places provided in the bioanalytical report).*

Table 6.4: 1 Subject sets analysed

Class of analysis	Subject set	
	TS	PKS
Primary and further PK endpoints		X
Safety & treatment exposure	X	
Demographic & baseline characteristics	X	



## **6.6 HANDLING OF MISSING DATA AND OUTLIERS**

Handling of missing data and outliers will be performed as described in the CTP, Section 7.3: Missing or incomplete AE dates are imputed according to BI standards (see BI-KMED-BDS-HTG-0035) (5).

Missing data and outliers of PK data are handled according to BI standards (see “Standards and processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics” (6) and “Noncompartmental Pharmacokinetic / Pharmacodynamic Analyses of Clinical Studies” (7)).

PK parameters that cannot be reasonably calculated based on the available drug concentration-time data will not be imputed.

## **6.7 BASELINE, TIME WINDOWS AND CALCULATED VISITS**

The baseline value is defined as the last measurement before trial drug administration.

### **Section 6.1 of the CTP:**

*Exact times of measurements outside the permitted time windows will be documented. The acceptable time windows for screening and the end of trial examination are provided in the CTP Flow Chart.*

*Trial measurements and assessments scheduled to occur ‘before’ trial medication administration on Day 1 are to be performed and completed within a 3 h-period prior to the trial drug administration.*

*The acceptable deviation from the scheduled time for vital signs, ECG, and blood laboratory tests will be  $\pm 30$  min for the first 24 h after trial drug administration and  $\pm 120$  min thereafter. Urine laboratory test can be performed between wake-up to the scheduled time.*

Proprietary confidential information © 2024 Boehringer Ingelheim International GmbH or one or more of its affiliated companies.

*If several activities are scheduled at the same time point in the CTP Flow Chart, ECG should be the first and meal the last activity. Furthermore, if several measurements including venipuncture are scheduled for the same time, venipuncture should be the last of the measurements due to its inconvenience to the subject and possible influence on physiological parameters.*

*For planned blood sampling times, refer to the CTP Flow Chart. While these nominal times should be adhered to as closely as possible, the actual sampling times will be recorded and used for the determination of pharmacokinetic parameters.*

Adherence to time windows will be checked via the consistency check listings at the RPM.

Unscheduled measurements of laboratory data and vital signs data will be assumed to be repeat measurements of the most recent scheduled measurement (e.g. for follow-up or confirmation of a particular value). Therefore, unscheduled measurements will be assigned to the planned time point of the previous scheduled measurement.

## **7. PLANNED ANALYSIS**

Safety analysis (refer to [Section 7.8](#)) will be performed by [REDACTED] and will be presented in Sections 15.1 to 15.4 of the CTR and in Appendix 16.2 and 16.1.13.1.

Descriptive data analysis of PK endpoints and concentrations will be performed by [REDACTED] and monitored by the [REDACTED] and will be presented in Section 15.6 of the CTR and in Appendix 16.1.13.5.

The format of the listings and tables will follow the BI standards (see “Standards for Reporting of Clinical Trials and Project Summaries” ([8](#))) with the exception of those generated for PK-calculations following BI standards for PK/PD analysis ([9](#)).

The individual values of all subjects will be listed, sorted by treatment group, subject number and visit. The listings will be included in Appendix 16.2 of the CTR.

The following standard descriptive statistical parameters will be displayed in summary tables of continuous variables:

N	number non-missing observations
Mean	arithmetic mean
SD	standard deviation
Min	minimum
Median	median
Max	maximum

For analyte concentrations and PK parameters, the following descriptive statistics will additionally be calculated:

Nobs	number of observations
CV	arithmetic coefficient of variation
gMean	geometric mean
gCV	geometric coefficient of variation
P10	10 <sup>th</sup> percentile
Q1	1 <sup>st</sup> quartile
Q3	3 <sup>rd</sup> quartile
P90	90 <sup>th</sup> percentile

The data format for descriptive statistics of concentrations will be identical to the data format of the respective concentrations. The descriptive statistics of PK parameters will be calculated using the individual values with the number of decimal places as provided by the evaluation program. Then the individual values as well as the descriptive statistics will be reported with three significant digits in the CTR.

Tabulations of frequencies for categorical data will include all possible categories available in the CRF and will display the number of observations in a category, as well as the percentage (%). Percentages will be given in integer numbers due to the small sample size of <100. Percentages will be based on all subjects in the respective subject set whether they have non-

missing values or not. The category 'missing' will be displayed only if there are actually missing values.

Units of variables should be given in the titles or column/row descriptors in brackets (e.g. (mg)).

#### Exclusion of PK parameters

The ADS “ADPP” (PK parameters) contains column variables APEX and APEXCO indicating inclusion/exclusion (APEX) of a PK parameter and an analysis flag comment (APEXCO). All analyses based on the PKS will include parameters only if they are not flagged for exclusion, that is APEX is equal to “Included”.

#### Exclusion of PK concentrations

The ADS “ADPC” (PK concentrations per time-point or per time-interval) contains column variables ACEX and ACEXCO indicating inclusion/exclusion (ACEX) of a concentration and an analysis flag comment (ACEXCO). Exclusion of a concentration depends on the analysis flag comment ACEXCO. For example, if ACEXCO is set to

- ‘ALL CALC’, the value will be excluded for all types of analyses based on concentrations.
- ‘DESC STATS’ the value will be excluded from descriptive evaluations per planned time point/time interval.
- to ‘HALF LIFE’, the value will be excluded from half-life calculation (and, as a consequence, any calculation that relies on  $\lambda_z$ ) only; the value is included for all other analyses.

If ACEXCO contains the addition ‘TIME VIOLATION’ or ‘TIME DEVIATION’ the value can be used for further analyses based on actual times. Excluded concentration itself will be listed in the CTR associated with an appropriate flag.

Further details are given in “Noncompartmental Pharmacokinetic / Pharmacodynamic Analyses of Clinical Studies” ([7](#)) and “Description of Analytical Transfer Files and PK/PD Data Files” ([10](#)).

## **7.1 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS**

Only descriptive statistics are planned for this section of the report, based on the TS. The data will be summarised by treatment group and in total.

## **7.2 CONCOMITANT DISEASES AND MEDICATION**

Only descriptive statistics are planned for this section of the report, based on the TS.

Concomitant diseases and non-drug therapies will be coded according to the version defined in the decision log (4) of the coding system of the Medical Dictionary for Drug Regulatory Activities (MedDRA). Concomitant medications will be coded according to the most recent version of the World Health Organization Drug Dictionary (WHO-DD). The coding version number will be displayed as a footnote in the respective output.

### **Section 7.2.5 of the CTP:**

*Previous and concomitant therapies will be presented per treatment group without consideration of time intervals and treatment periods.*

The diagnoses and medications will be listed. Subjects without any concomitant diagnoses or concomitant therapies will be marked with a “No” in the respective column.

The relevance of the concomitant therapies to the evaluation of PK data will be decided no later than at the RPM.

## **7.3 TREATMENT COMPLIANCE**

### **Section 4.3 of the CTP:**

*Compliance will be assured by administration of all trial medication in the trial centre under supervision of the investigating physician or a designee. The measured plasma concentrations of trial medication will provide additional confirmation of compliance.*

Only descriptive statistics are planned for this section of the report, based on the TS.


It is not intended to list the compliance separately. Any deviations from complete intake will be addressed in the RPM and described in the CTR.

## **7.4 PRIMARY OBJECTIVE ANALYSIS**

### **7.4.1 Main analysis**

#### **Section 7.2.2 of the CTP:**

*The primary endpoints as specified in Section 5.1 will be derived according to BI standards. The analysis will be based on the PKS and will be descriptive in nature.*



#### **7.4.4 Supplementary analysis**

No subgroup analysis is planned.

### **7.5 SECONDARY OBJECTIVE ANALYSIS**

#### **7.5.1 Key secondary objective analysis**

This section is not applicable as no key secondary objective has been specified in the protocol.

#### **7.5.2 Secondary objective analysis**

This section is not applicable as no secondary objective has been specified in the protocol.

### **7.6 FURTHER OBJECTIVE ANALYSIS**

#### Pharmacokinetic endpoints

Further PK endpoints will be analysed descriptively, based on the PKS.

#### Safety endpoints

For a description of the analysis of safety and tolerability, please refer to [Section 7.8](#).

### **7.7 EXTENT OF EXPOSURE**

Descriptive statistics are planned for this section of the report based on the TS. The date and time of drug administration will be listed for each subject.

### **7.8 SAFETY ANALYSIS**

All safety analyses will be performed on the TS.

The safety data for treated subjects who failed to complete the study (dropouts or withdrawals) will be reported as far as their data are available. All withdrawals will be documented and the reason for withdrawal recorded.

#### **7.8.1 Adverse Events**

AEs will be coded using MedDRA. The coding version number will be displayed as a footnote in the respective output.

Unless otherwise specified, the analyses of AEs will be descriptive in nature. All analyses of AEs will be based on the number of subjects with AEs and NOT on the number of AEs. BI standards as presented in “Analysis and Presentation of Adverse Event Data from Clinical Trials – Display Template” ([11](#)) and “Analysis and Presentation of AE data from clinical trials” ([12](#)) will be applied.

The analysis of AEs will be based on the concept of treatment emergent AEs. That means that all AEs will be assigned to 'screening', 'on-treatment' or 'follow-up' phases as defined in [Section 6.1](#). AEs will be analysed based on actual treatments, as defined in [Table 6.1: 1](#).

According to the clinical study protocol, adverse events of special interest (AESI) will be analysed:

#### Section 5.2.6.1.4 of the CTP:

*The following are considered as AESIs:*

- Potential severe DILI  
*A potential severe Drug Induced Liver Injury (DILI) that requires follow-up is defined by the following alterations of hepatic laboratory parameters:*
  - *An elevation of AST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) =3-fold ULN combined with an elevation of total bilirubin =2-fold ULN measured in the same blood sample, or in samples drawn within 30 days of each other, or*
  - *Aminotransferase (ALT, and/or AST) elevations =10-fold ULN*

*These lab findings constitute a hepatic injury alert and the subjects showing these lab abnormalities need to be followed up according to the 'DILI checklist' provided in the ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should make sure that these parameters are analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the procedures described in the DILI checklist should be followed.*

- *Severe or serious infections, opportunistic or mycobacterium tuberculosis infections*  
*The opportunistic infections include pneumocystis jirovecii, Human Polyoma-1 virus disease including polyomavirus-associated nephropathy, Cytomegalie Virus, posttransplant lymphoproliferative disorder (Epstein-Barr-Virus), progressive multifocal leucoencephalopathy, bartonellosis (disseminated only), blastomycosis, toxoplasmosis, coccidioidomycosis, histoplasmosis, aspergillosis (invasive only), candidiasis (invasive or pharyngeal), cryptococcosis, other invasive fungi (mucormycosis (zygomycosis, rhizopus, mucor, lichtheimia), scedosporium/ pseudallescheria boydii, fusarium), legionellosis, listeria monocytogenes (invasive only), tuberculosis, nocardiosis, non-tuberculous mycobacterium, salmonellosis (invasive only), HBV reactivation, herpes simplex (invasive only), herpes zoster, strongyloides (hyperinfection syndrome and disseminated forms only), paracoccidioides, penicillium marneffei, sporothrix schenckii, cryptosporidium species (chronic only), microsporidiosis, leishmaniasis (visceral only), trypanosome cruzi infection (Chagas' disease) (disseminated only), campylobacteriosis (invasive only), shigellosis (invasive only), vibriosis (invasive due to vibrio vulnificus), Hepatitis C progression*

- *Vasculitis events*

*In this trial protocol vasculitis is defined as any event term included in the MedDRA SMQ Vasculitis (broad). This includes clinical and pathological features related to primary or secondary vasculitis syndromes and involving any type, size, and location of blood vessels.*

According to ICH E3 ([13](#)), in addition to Deaths and serious adverse events, ‘other significant’ AEs need to be listed in the clinical trial report. These will be any non-serious adverse event that led to an action taken with study drug (e.g. discontinuation or dose reduced or interrupted).

An overall summary of adverse events will be presented.

The frequency of subjects with AEs will be summarised by treatment, primary system organ class (SOC) and preferred term (PT). Separate tables will be provided for subjects with serious AEs, for subjects with drug-related AEs, for subjects with drug-related serious adverse events and for subjects with AESIs. In addition, the frequency of subjects with AEs will be summarised by treatment, worst intensity, primary system organ class (SOC) and preferred term (PT).

The system organ classes will be sorted by default alphabetically, PTs will be sorted by descending frequency (within SOC).

In addition, frequencies of subjects with non-serious AEs that had an incidence of > 5% for at least one treatment will be summarised by treatment, primary SOC and PT.

### **7.8.2 Laboratory data**

The analyses of laboratory data will be descriptive in nature and will be based on BI standards as presented in “Handling, Display and Analysis of Laboratory Data” ([14](#)). Analyses will be based on normalised values, which means transforming to a standard unit and a standard reference range. The original values will be analysed if the transformation into standard unit is not possible for a parameter.

Laboratory data will be analysed qualitatively via comparison of laboratory data to their reference ranges. Values outside the reference range as well as values defined as possibly clinically significant will be flagged in the data listings.

Clinically relevant findings in laboratory data will be reported as baseline conditions (at screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and will be analysed as such.

It is the investigator's responsibility to decide whether a lab value is clinically significantly abnormal or not (at the RPM at the latest).

For post-dose measurement of laboratory data, descriptive statistics over time including change from baseline will be calculated by planned time point based on the first value of the subject at that planned time point (or assigned to that planned time point).

### **7.8.3 Vital signs**

Descriptive statistics over time including change from baseline will be performed for vital signs (blood pressure and pulse rate). In the listing the change from baseline will also be displayed.

For post-dose measurements of vital signs, descriptive statistics will be calculated by planned time point based on the first value of the subject at that planned time point (or assigned to that planned time point).

Clinically relevant findings will be reported as baseline conditions (at screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and will be analysed as such.

### **7.8.4 ECG**


Clinically relevant abnormal findings will be reported as adverse events.  
No separate listing or analysis of continuous ECG monitoring will be prepared.

## **7.9 OTHER ANALYSIS**

### Physical examination

Physical examination findings will be reported as relevant medical history/baseline condition (i.e., a condition already existent before intake of trial drug) or as AE and will be summarised as such.

No separate listing or analysis of physical examination findings will be prepared.




## **8. TIMEPOINT OF RELEASE OF TREATMENT INFORMATION**

Not applicable due to open label fashion of the trial as described in the CTP section 4.1.5.

## **9. REFERENCES**

1.	<i>CPMP/ICH/363/96</i> : “Statistical Principles for Clinical Trials”, ICH Guideline Topic E9, Note For Guidance on Statistical Principles for Clinical Trials, current version.
2.	<i>001-MCS-40-413</i> : “Identify and Manage Important Protocol Deviations (iPD)”, current version, Group “Clinical Operations”, IDEA for CON.
3.	<i>BI-KMED-BDS-TMP-0059</i> : “iPD specification document (sdtm-dv-domain-specification)”, template, current version, KMED.
4.	<i>001-MCS-50-415_RD-03</i> : “Clinical Trial Analysis Decision Log (template) Decision Log”, current version, Group “Biostatistics & Data Sciences”, IDEA for CON.
5.	<i>BI-KMED-BDS-HTG-0035</i> : “Handling of Missing and Incomplete AE Dates”, current version; KMED.
6.	<i>BI-KMED-TMCP-HTG-0025</i> : “Standards and processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics”, current version; KMED.
7.	<i>BI-KMED-TMCP-MAN-0014</i> : “Noncompartmental Pharmacokinetic / Pharmacodynamic Analyses of Clinical Studies”, current version; KMED.
8.	<i>BI-KMED-BDS-HTG-0045</i> : “Standards for Reporting of Clinical Trials and Project Summaries”, current version; KMED.
9.	<i>BI-KMED-TMCP-OTH-0003</i> : “Graphs and Tables for Clinical Pharmacokinetics and Pharmacodynamic Noncompartmental Analyses”, current version, KMED.
10.	<i>BI-KMED-TMCP-MAN-0010</i> : “Description of Analytical Transfer Files and PK/PD Data Files”, current version; KMED.
11.	<i>BI-KMED-BDS-HTG-0041</i> : “Analysis and Presentation of Adverse Event Data from Clinical Trials – Display Template”, current version; KMED.
12.	<i>BI-KMED-BDS-HTG-0066</i> : “Analysis and Presentation of AE data from clinical trials”, current version, KMED.
13.	<i>CPMP/ICH/137/95</i> : “Structure and Content of Clinical Study Reports”, ICH Guideline Topic E3; Note For Guidance on Structure and Content of Clinical Study Reports, current version, EMA webpage.
14.	<i>BI-KMED-BDS-HTG-0042</i> : “Handling, Display and Analysis of Laboratory Data”, current version; KMED.

Proprietary confidential information © 2024 Boehringer Ingelheim International GmbH or one or more of its affiliated companies.



## **11. HISTORY TABLE**

Table 11: 1 History table

<b>Version</b>	<b>Date (DD-MMM- YY)</b>	<b>Author</b>	<b>Sections changed</b>	<b>Brief description of change</b>
1.0	<b>19-MAR-24</b>		None	This is the final TSAP.